RT Journal Article
SR Electronic
T1 Safe Injection Self-Efficacy is associated with HCV and HIV seropositivity among people who inject drugs in the San Diego-Tijuana border region
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.21.24307696
DO 10.1101/2024.05.21.24307696
A1 Bailey, Katie
A1 Abramovitz, Daniela
A1 Rangel, Gudelia
A1 Harvey-Vera, Alicia
A1 Vera, Carlos F.
A1 Patterson, Thomas L.
A1 Sánchez-Lira, Jaime Arredondo
A1 Davidson, Peter J.
A1 Garfein, Richard S.
A1 Smith, Laramie R.
A1 Pitpitan, Eileen V.
A1 Goldenberg, Shira M.
A1 Strathdee, Steffanie A.
YR 2024
UL http://medrxiv.org/content/early/2024/05/22/2024.05.21.24307696.abstract
AB Background Safe injection self-efficacy (SISE) is negatively associated with injection risk behaviors among people who inject drugs (PWID) but has not been examined in differing risk environments. We compared responses to a validated SISE scale between PWID in San Diego, California and Tijuana, Mexico, and examine correlates of SISE among PWID in Tijuana.Methods PWID were recruited via street outreach for a longitudinal cohort study from October 2020 – September 2021. We compared SISE scale items by city. Due to low variability in SISE scores among San Diego residents, we restricted analysis of factors associated with SISE to Tijuana residents and identified correlates of SISE scores (low, medium, high) using ordinal logistic regression.Results Of 474 participants, most were male (74%), Latinx (78%) and Tijuana residents (73%). Mean age was 44. Mean SISE scores among San Diego residents were high (3.46 of 4 maximum) relative to Tijuana residents (mean: 1.93). Among Tijuana residents, White race and having previously resided in San Diego were associated with higher SISE scores. HCV and HIV seropositivity, homelessness, fentanyl use, polysubstance co-injection, and greater injection frequency were associated with lower SISE scores.Conclusions We found profound inequalities between Tijuana and San Diego SISE, likely attributable to differential risk environments. Associations with fentanyl and polysubstance co-injection, injection frequency, and both HIV and HCV seropositivity suggest that SISE contribute to blood-borne infection transmission risks in Tijuana. SISE reflects an actionable intervention target to reduce injection risk behaviors, but structural interventions are required to intervene upon the risk environment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute on Drug Abuse (NIDA) (grant R01DA049644-05, PI: Steffanie A. Strathdee). This work was also made possible with help from the San Diego Center for AIDS Research (SD CFAR), a National Institutes of Health (NIH)-funded program (grant P30AI036214). Jaime Arredondo Sanchez-Liras work was supported by the Canada Research Chair Program. Laramie R. Smith was supported by NIDA (grant R34DA059327-01). Katie Bailey received funding from NIDA (grant T32DA023356-17) and San Diego State University (University Graduate Fellowship).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at The University of California San Diego and Xochicalco University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.